Short reportsRandomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine
References (11)
- et al.
Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: II, haemodialysis patients
Lancet
(1981) - et al.
Hepatitis B vaccination and interleukin-2 receptor expression in chronic renal failure
Kidney Int
(1990) - et al.
Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination
Lancet
(1989) - et al.
Active hepatitis B vaccination of dialysis patients and medical staff
Kidney Int
(1984) - et al.
Hepatitis B vaccine: randomized trial in immunogenicity in hemodialysis patients
Clin Nephrol
(1984)
Cited by (67)
Management of hepatitis B virus and hepatitis C virus infection in chronic kidney failure
2015, Nephrologie et TherapeutiqueHepatitis B virus vaccine in chronic kidney disease: Improved immunogenicity by adjuvants? A meta-analysis of randomized trials
2012, VaccineCitation Excerpt :A complete list of the 133 reports reviewed is available from the authors on request. A total of nine reports giving information on ten RTCs were included in our meta-analysis [19–27]. There was a 100% concordance between reviewers with respect to final inclusion and exclusion of studies reviewed based on the predefined inclusion and exclusion criteria.
VIRAL hepatitis in solid organ transplantation other than liver
2011, Journal of HepatologyEnhancement of the immune responses to vaccination against foot-and-mouth disease in mice by oral administration of an extract made from Rhizoma Atractylodis Macrocephalae (RAM)
2009, VaccineCitation Excerpt :Therefore, there is a need to improve currently available vaccines in order to effectively protect humans and animals from infection. Strategies to improve the immune response to vaccination have included the use of higher vaccine dose or increasing number of doses, use of different route of administration (e.g., intradermal versus intramuscular administration), accelerating dosing schedule and use of adjuvants such as antigen delivery systems and various immunomodulators [8–16] There is growing evidence that medicinal herbs and the ingredients enhance the immune response to vaccines direct against infectious agents [17,18]. Medicinal herbs have a variety of effects on immune responses and co-administration with herbal extracts has been shown to increase the antibody response and to enhance the proliferative response of T cells [19,20].
Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination: A meta-analysis
2007, VaccineCitation Excerpt :Actually, the antibody response is lower in patients with diabetes mellitus, renal failure and chronic liver disease, as well as in immunocompromised patients, such as those infected with HIV. Strategies to improve the HBV vaccine response rate have included the use of higher vaccine dose or increasing number of doses, use of different route of administration (e.g., intradermal versus intramuscular administration), accelerating dosing schedule and use of adjuvants such as antigen delivery systems and various immunomodulators [3,9–17]. There is growing evidence that granulocyte macrophage colony-stimulating factor (GM-CSF) enhances the immune response to vaccines direct against both infectious agents and various cancers [16,17].
The use of vaccines in adult patients with renal disease
2005, American Journal of Kidney Diseases